Genetic and immune changes associated with disease progression under the pressure of oncolytic therapy in a neuroblastoma outlier patient

Biblos-e Archivo/Manakin Repository

Show simple item record

dc.contributor.author Franco-Luzón, Lidia
dc.contributor.author García-Mulero, Sandra
dc.contributor.author Sanz-Pamplona, Rebeca
dc.contributor.author Melen, Gustavo
dc.contributor.author Ruano, David
dc.contributor.author Lassaletta, Álvaro
dc.contributor.author Madero, Luís
dc.contributor.author González-Murillo, África
dc.contributor.author Ramírez, Manuel
dc.contributor.other UAM. Departamento de Pediatría es_ES
dc.contributor.other Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP) es_ES
dc.date.accessioned 2021-02-10T14:53:20Z
dc.date.available 2021-02-10T14:53:20Z
dc.date.issued 2020-04-28
dc.identifier.citation Cancers 12.5 (2020): 1104 en_US
dc.identifier.issn 2072-6694 es_ES
dc.identifier.uri http://hdl.handle.net/10486/693393
dc.description.abstract Little is known about the effect of oncolytic adenovirotherapy on pediatric tumors. Here we present the clinical case of a refractory neuroblastoma that responded positively to Celyvir (ICOVIR-5 oncolytic adenovirus delivered by autologous mesenchymal stem cells) for several months. We analyzed samples during tumor evolution in order to identify molecular and mutational features that could explain the interactions between treatment and tumor and how the balance between both of them evolved. We identified a higher adaptive immune infiltration during stabilized disease compared to progression, and also a higher mutational rate and T-cell receptor (TCR) diversity during disease progression. Our results indicate an initial active role of the immune system controlling tumor growth during Celyvir therapy. The tumor eventually escaped from the control exerted by virotherapy through acquisition of resistance by the tumor microenvironment that exhausted the initial T cell response. en_US
dc.description.sponsorship This research was funded by Instituto de Salud Carlos III, grant number PI13/02487 and PI16/02008. The APC was funded by Asociación Pablo Ugarte, Asociación NEN and Fundación Neuroblastoma en_US
dc.format.extent 17 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en_US
dc.publisher MDPI, Basel, Switzerland en_US
dc.relation.ispartof Cancers en_US
dc.rights © 2020 The Authors en_US
dc.subject.other Bioinformatic analysis en_US
dc.subject.other Immune landscape en_US
dc.subject.other Neuroblastoma en_US
dc.subject.other Oncolytic virotherapy en_US
dc.subject.other T lymphocytes (TILs) en_US
dc.title Genetic and immune changes associated with disease progression under the pressure of oncolytic therapy in a neuroblastoma outlier patient en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.relation.publisherversion http://doi.org/10.3390/cancers12051104 es_ES
dc.identifier.doi 10.3390/cancers12051104 es_ES
dc.identifier.publicationfirstpage 1104-1 es_ES
dc.identifier.publicationissue 5 es_ES
dc.identifier.publicationlastpage 1104-17 es_ES
dc.identifier.publicationvolume 12 es_ES
dc.relation.projectID Gobierno de España. PI13/02487 es_ES
dc.relation.projectID Gobierno de España. PI16/02008 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en
dc.rights.cc Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Madero López, Luis (100007)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record